CHROMATE ION CR-51

US Previously Marketed

First approved in 1952

Details

Stereochemistry	ACHIRAL
Molecular Formula	CrO4
Molecular Weight	114.9424
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	-2

SHOW SMILES / InChI

Structure Search

SMILES

[O-][51Cr]([O-])(=O)=O

InChI

InChIKey=ZCDOYSPFYFSLEW-HONVGLGOSA-N

InChI=1S/Cr.4O/q;;;2*-1/i1-1;;;;

HIDE SMILES / InChI

Molecular Formula	CrH2O4
Molecular Weight	116.9583
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.drugs.com/pro/chromitope.html#s-34084-4 | https://www.ncbi.nlm.nih.gov/pubmed/29999757 | https://pharmacyce.unm.edu/nuclear_program/neolibrary/libraryfiles/package_inserts/Chromitope%20Sodium.pdf | http://www.druglib.com/druginfo/chromitope/indications_dosage/

Chromate ion CR-51 is a radioactive chromium 51 in the form of sterile, nonpyrogenic aqueous solution of sodium chromate. It is a diagnostic radiopharmaceutical for intravenous administration. This agent provides Chromium 51 decays by electron capture and gamma emission with a physical half-life of 27.7 days. It is indicated for use in determining red blood cell volume or mass, studying red blood cell survival time (in conditions such as hemolytic anemia), and evaluating blood loss. No adverse reactions specifically attributable to Chromate ion CR-51 injection have been reported.

Approval Year

Conditions

Condition	Modality	Highest Phase	Product
Polycythemia 2 Sources: https://www.drugs.com/pro/sodium-chromate-cr-51.html	Diagnostic	Approved 8583	SODIUM CHROMATE CR 51 Approved Use Cr51 is indicated for use in determining red blood cell volume or mass, studying red blood cell survival time (in conditions such as hemolytic anemia), and evaluating blood loss Launch Date 1971
Hereditary spherocytosis 2 Sources: https://www.drugs.com/pro/sodium-chromate-cr-51.html	Diagnostic	Approved 8583	SODIUM CHROMATE CR 51 Approved Use Cr51 is indicated for use in determining red blood cell volume or mass, studying red blood cell survival time (in conditions such as hemolytic anemia), and evaluating blood loss Launch Date 1971
Acquired hemolytic anemia 2 Sources: https://www.drugs.com/pro/sodium-chromate-cr-51.html	Diagnostic	Approved 8583	SODIUM CHROMATE CR 51 Approved Use Cr51 is indicated for use in determining red blood cell volume or mass, studying red blood cell survival time (in conditions such as hemolytic anemia), and evaluating blood loss Launch Date 1971

Sample Use Guides

In Vivo Use Guide

The usual doses to the average patient (70 kg) are as follows: Determination of red blood cell volume or mass–0.37 to 1.11 megabecquerels (10 to 30 microcuries). Study of red blood cell survival time–5.55 megabecquerels (150 microcuries). Evaluation of blood loss–7.40 megabecquerels (200 microcuries).

Route of Administration: Intravenous

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:36:02 GMT 2025` Edited by `admin` on `Mon Mar 31 18:36:02 GMT 2025`
Record UNII	SVU4HTP02M
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CHROMATE ION CR-51

Preferred Name

English

Classification Tree Code System Code

NDF-RT

N0000177914